DK3366307T3 - Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri - Google Patents

Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri Download PDF

Info

Publication number: DK3366307T3
Authority: DK; Denmark
Prior art keywords: masp; nokturn; hemoglobinuri; paroxystic; compositions
Prior art date: 2012-04-06

Application number

DK18158799.9T

Other languages

English (en)

Inventor

Gregory Demopulos

Hans-Wilhelm Schwaeble

Original Assignee

Omeros Corp

Univ Leicester

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2013-04-05

Publication date

2021-11-01

2013-04-05 Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp

2021-11-01 Application granted granted Critical

2021-11-01 Publication of DK3366307T3 publication Critical patent/DK3366307T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Mechanical Treatment Of Semiconductor (AREA)

DK18158799.9T 2012-04-06 2013-04-05 Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri DK3366307T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261621461P	2012-04-06	2012-04-06
EP13798222.9A EP2833907B1 (en)	2012-04-06	2013-04-05	Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number	Publication Date
DK3366307T3 true DK3366307T3 (da)	2021-11-01

Family

ID=49325295

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13798222.9T DK2833907T3 (da)	2012-04-06	2013-04-05	Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri
DK18158799.9T DK3366307T3 (da)	2012-04-06	2013-04-05	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13798222.9T DK2833907T3 (da)	2012-04-06	2013-04-05	Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri

Country Status (29)

Country	Link
US (3)	US20130273053A1 (da)
EP (2)	EP3366307B1 (da)
JP (3)	JP6366571B2 (da)
KR (2)	KR102318623B1 (da)
CN (1)	CN104661676A (da)
AU (3)	AU2013267909B2 (da)
BR (1)	BR112014024793A2 (da)
CA (2)	CA2869326C (da)
CL (1)	CL2014002694A1 (da)
CY (1)	CY1120736T1 (da)
DK (2)	DK2833907T3 (da)
ES (2)	ES2894944T3 (da)
HK (1)	HK1206996A1 (da)
HR (1)	HRP20180671T1 (da)
HU (1)	HUE036930T2 (da)
IL (2)	IL234991B (da)
IN (1)	IN2014KN02324A (da)
LT (1)	LT2833907T (da)
MX (2)	MX2018008658A (da)
NO (1)	NO2881536T3 (da)
NZ (2)	NZ629675A (da)
PL (2)	PL2833907T3 (da)
PT (1)	PT2833907T (da)
RS (1)	RS57266B1 (da)
RU (2)	RU2018114903A (da)
SI (1)	SI2833907T1 (da)
TR (1)	TR201806939T4 (da)
WO (1)	WO2013180834A2 (da)
ZA (1)	ZA201408100B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9011860B2 (en) *	2011-05-04	2015-04-21	Omeros Corporation	Compositions for inhibiting MASP-2 dependent complement activation
PL2861246T3 (pl) *	2012-06-18	2021-10-25	Omeros Corporation	Kompozycje i sposoby hamowania MASP-1 i/lub MASP-2 i/lub MASP-3 w leczeniu różnych chorób i zaburzeń
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
EP2968546B1 (en)	2013-03-15	2023-09-20	Omeros Corporation	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TWI797097B (zh)	2016-11-28	2023-04-01	日商中外製藥股份有限公司	包含抗原結合域與運送部分的多胜肽
KR102533814B1 (ko)	2016-11-28	2023-05-19	추가이 세이야쿠 가부시키가이샤	리간드 결합 활성을 조정 가능한 리간드 결합 분자
JP7409871B2 (ja) *	2017-04-03	2024-01-09	中外製薬株式会社	抗ｍａｓｐ－１抗体およびその使用方法
AU2018377783A1 (en)	2017-11-28	2020-06-11	Chugai Seiyaku Kabushiki Kaisha	Polypeptide including antigen-binding domain and carrying section
WO2019230867A1 (en)	2018-05-30	2019-12-05	Chugai Seiyaku Kabushiki Kaisha	Polypeptide comprising aggrecan binding domain and carrying moiety
WO2021021909A1 (en) *	2019-07-31	2021-02-04	Biocryst Pharmaceuticals, Inc.	Dosing regimens for oral complement factor d inhibitors
JP2023504543A (ja)	2019-12-04	2023-02-03	オメロスコーポレーション	Ｍａｓｐ－２阻害剤および使用方法
WO2021113698A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
IL293588A (en)	2019-12-04	2022-08-01	Omeros Corp	2-masp inhibitor compounds, preparations containing them and their uses
JP2023538914A (ja)	2020-08-18	2023-09-12	オメロスコーポレーション	補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
CN114295594B (zh) *	2021-12-06	2023-09-19	贵州理工学院	一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE69030172T2 (de)	1990-01-26	1997-06-19	Immunomedics Inc	Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
CA2391402A1 (en) *	1999-12-02	2001-06-07	Jens Christian Jensenius	Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) *	2001-07-23	2006-05-09	Intel Corporation	Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
AU2003249317B2 (en)	2002-07-19	2007-08-02	Institute Of Materials Research And Engineering	Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
CA2515453C (en) *	2003-02-21	2013-09-24	Tanox, Inc.	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
EP1713929A2 (en) *	2004-02-03	2006-10-25	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US7803931B2 (en) *	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko)	2005-08-19	2014-05-07	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
DE602006004582D1 (de) *	2006-07-31	2009-02-12	Fiat Ricerche	Durch eine Fluidströmung betätigbarer elektrischer Generator
JP5537420B2 (ja)	2007-05-31	2014-07-02	ユニヴァーシティオブワシントン	標的遺伝子の誘導性変異誘発
KR20110047255A (ko) *	2008-09-26	2011-05-06	로슈 글리카트 아게	이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
EP2385843A4 (en) *	2009-01-06	2013-02-27	Dyax Corp	TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
JP2012519555A (ja) *	2009-03-05	2012-08-30	スミスアンドネフューインコーポレーテッド	大腿骨頚ガイドワイヤーの位置決め用のシステム、方法、及び装置
WO2011006982A2 (en) *	2009-07-17	2011-01-20	Rigshospitalet	Inhibitors of complement activation
EA201290286A1 (ru) *	2009-11-05	2013-01-30	Алексион Кембридж Корпорейшн	Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
KR20210021101A (ko)	2011-04-08	2021-02-24	유니버시티 오브 레스터	Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법

2013
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/da active
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending

Also Published As

Publication number	Publication date
HK1206996A1 (en)	2016-01-22
NZ629675A (en)	2017-02-24
JP6815355B2 (ja)	2021-01-20
AU2020204163A1 (en)	2020-07-09
LT2833907T (lt)	2018-06-11
CY1120736T1 (el)	2019-12-11
MX2014012045A (es)	2015-05-15
TR201806939T4 (tr)	2018-06-21
KR20150003785A (ko)	2015-01-09
WO2013180834A2 (en)	2013-12-05
WO2013180834A3 (en)	2014-04-03
EP2833907A2 (en)	2015-02-11
CA3087933A1 (en)	2013-12-05
RU2018114903A (ru)	2019-03-04
AU2018200721B2 (en)	2020-03-26
EP2833907A4 (en)	2016-03-16
US20190382505A1 (en)	2019-12-19
IL274721B (en)	2022-04-01
RU2014144621A (ru)	2016-05-27
US20130273053A1 (en)	2013-10-17
DK2833907T3 (da)	2018-05-28
NZ781091A (en)	2022-04-29
AU2018200721A1 (en)	2018-02-22
CA2869326C (en)	2021-09-21
KR102142508B1 (ko)	2020-08-10
MX357540B (es)	2018-07-13
NO2881536T3 (da)	2018-06-30
KR20200097808A (ko)	2020-08-19
BR112014024793A2 (pt)	2019-08-27
SI2833907T1 (en)	2018-07-31
JP2015514117A (ja)	2015-05-18
CN104661676A (zh)	2015-05-27
CL2014002694A1 (es)	2015-08-28
EP3366307A1 (en)	2018-08-29
PL2833907T3 (pl)	2018-08-31
PT2833907T (pt)	2018-05-29
JP2018162307A (ja)	2018-10-18
RU2655299C2 (ru)	2018-05-24
IL234991B (en)	2020-06-30
AU2013267909A1 (en)	2014-11-27
PL3366307T3 (pl)	2022-03-07
ZA201408100B (en)	2022-05-25
NZ727063A (en)	2021-10-29
RU2018114903A3 (da)	2021-08-12
IN2014KN02324A (da)	2015-05-01
JP6366571B2 (ja)	2018-08-01
AU2013267909B2 (en)	2018-03-01
IL274721A (en)	2020-07-30
RS57266B1 (sr)	2018-08-31
ES2670668T3 (es)	2018-05-31
JP2021001199A (ja)	2021-01-07
MX2018008658A (es)	2021-10-19
CA2869326A1 (en)	2013-12-05
ES2894944T3 (es)	2022-02-16
EP3366307B1 (en)	2021-07-28
EP2833907B1 (en)	2018-02-28
US20220242972A1 (en)	2022-08-04
HUE036930T2 (hu)	2018-08-28
KR102318623B1 (ko)	2021-11-02
HRP20180671T1 (hr)	2018-07-13
IL234991A0 (en)	2014-12-31

Publication	Publication Date	Title
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2898061T3 (da)	2020-02-10	Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK2818481T3 (da)	2019-10-14	Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2929031T5 (da)	2021-08-23	Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3444342T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK3119797T3 (da)	2021-03-15	Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK2776567T3 (da)	2021-04-26	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK3234133T3 (da)	2021-02-08	Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3252160T3 (da)	2021-02-01	Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2935303T3 (da)	2021-05-03	4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK3035955T3 (da)	2019-12-02	Sammensætning og vaccine til behandling af lungekræft
DK3007695T3 (da)	2024-03-18	Sammensætninger og fremgangsmåder til behandling af anæmi
DK2961831T3 (da)	2020-09-07	Sammensætninger og fremgangsmåder til immunterapi
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2841097T3 (da)	2022-11-28	Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK3685848T3 (da)	2021-12-13	Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3096798T3 (da)	2021-03-01	Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK2854850T3 (da)	2021-08-30	Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3277270T3 (da)	2021-12-06	Sammensætninger og fremgangsmåder til behandling af anæmi
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3209696T3 (da)	2021-08-09	Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3238707T3 (da)	2021-03-22	Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3189074T3 (da)	2021-04-19	Sammensætninger og metoder til behandling og forebyggelse af inflammation